Neurocrine biosciences presents data on in vitro dissolution performance of ingrezza® (valbenazine) capsule contents via soft foods or feeding tube at amda - paltc 2023 annual conference

San diego , march 9, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced it will present data from three in vitro dissolution studies exploring the dissolution performance of ingrezza® (valbenazine) capsule contents through soft foods or a gastrostomy (g-tube) feeding tube. the data (poster #ind03, valbenazine capsule contents for potential administration via soft food/feeding tube) will be presented at amda – the society for post-acute and long-term care medicine's paltc23 annual conference being held march 9-12 in tampa, florida.
NBIX Ratings Summary
NBIX Quant Ranking